MindMed Onboards Javier A. Muniz M.D. As Vice President of R&D Strategy
Mind Medicine (MindMed) Inc, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, recently announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed’s R&D operations as the Company prepares to […]
Seaport Therapeutics Winds Up USD 225Mn Series B Financing Round
Seaport Therapeutics, (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, recently announced the closing of an oversubscribed $225 million Series B financing round. According to Industry sources, this syndicate was powered by General Atlantic, a leading global growth investor, with participation from funds […]
Maryland Tech Council and BIOQuébec collaborate to promote life sciences
BIOQuébec and the Maryland Tech Council (MTC) are delighted to announce a new Memorandum of Understanding (MOU) that will enhance cooperation and collaboration between life sciences sectors in Québec and Maryland. This partnership aims to foster mutual benefits and strengthen biopharma and biotech industries in both regions through shared information and opportunities. The MOU establishes […]
Veristat welcomes Rachel Page as the new CCO
Veristat, the Science-First Full Service CRO and Consultancy, announced an appointment to its executive leadership team. Rachel Page joins Veristat as Chief Commercial Officer (CCO), succeeding Veristat’s longtime leader Cindy Henderson, who recently transitioned to become Chief Strategy Officer (CSO) to focus on developing and executing Veristat’s customer-driven corporate strategy. With over two decades of experience […]
Janux Therapeutics designates Zachariah McIver as Vice President, Clinical Development
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, yesterday announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development. An accomplished physician-scientist with more than 15 years […]
Huma and UCB partner to provide technology solution to help manage Myasthenia gravis
Huma Therapeutics (“Huma”), a leading global digital health company, and UCB, a global biopharmaceutical company, are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis (MG), better understand and manage their condition with the support of their clinician. The digital platform is launching in Europe ahead of international expansion. The […]
